Evaluation of rosiglitazone administration on cardiovascular function in severe obesity

Amelia Brunani, Antonio Liuzzi, AnnaMaria Titon, Salvatore Graci, Giovanna Castagna, Gian Carlo Viberti, Luca A. Gondoni

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Obese patients have myocardial structural and functional alterations related to insulin resistance. Hypothesis: The purpose of the study was to analyze the effects of rosiglitazone, an insulin sensitizer agent, on cardiac morphometry and functioning. Methods: In 2 groups of sex- and age-matched, nondiabetic, obese patients (5 men and 7 women, age 19-51 y; group A: body mass index [BMI] 40.6±3.4 kg/m2; group B: BMI 42.6±2.7 kg/m2), we evaluated the basal insulin sensitivity index (HOMA[IS]), body composition by bioelectrical impedance analysis and 24-h blood pressure monitoring. Furthermore, all patients underwent conventional 2-Dimensional and color Doppler echocardiography, and pulsed-wave tissue Doppler imaging (TDI). After the baseline evaluation, all patients were put on a hypocaloric diet (70% basal metabolic rate) plus placebo if they were in group A, or plus rosiglitazone (4 mg twice daily; Avandia [GlaxoSmithKline plc., Brentford, Middlesex, United Kingdom]) if they were in group B, for 6 mo. Results: Significant decreases in body weight, total fat mass, BMI, and systolic blood pressure were registered in both groups. Rosiglitazone administration appeared more efficient in improving HOMA(IS) (mean difference: 0.30±0.19 versus 0.11±0.21, p

Original languageEnglish
Pages (from-to)602-606
Number of pages5
JournalClinical Cardiology
Volume31
Issue number12
DOIs
Publication statusPublished - Dec 2008

Fingerprint

rosiglitazone
Morbid Obesity
Body Mass Index
Blood Pressure
Insulin Resistance
Doppler Color Echocardiography
Doppler Pulsed Echocardiography
Basal Metabolism
Body Composition
Electric Impedance
Age Groups
Fats
Placebos
Body Weight
Insulin
Diet

Keywords

  • Left ventricular function
  • Obesity
  • Rosiglitazone
  • Tissue doppler imaging

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Evaluation of rosiglitazone administration on cardiovascular function in severe obesity. / Brunani, Amelia; Liuzzi, Antonio; Titon, AnnaMaria; Graci, Salvatore; Castagna, Giovanna; Viberti, Gian Carlo; Gondoni, Luca A.

In: Clinical Cardiology, Vol. 31, No. 12, 12.2008, p. 602-606.

Research output: Contribution to journalArticle

Brunani, Amelia ; Liuzzi, Antonio ; Titon, AnnaMaria ; Graci, Salvatore ; Castagna, Giovanna ; Viberti, Gian Carlo ; Gondoni, Luca A. / Evaluation of rosiglitazone administration on cardiovascular function in severe obesity. In: Clinical Cardiology. 2008 ; Vol. 31, No. 12. pp. 602-606.
@article{82437f33ba4f4022b90b11f22103a642,
title = "Evaluation of rosiglitazone administration on cardiovascular function in severe obesity",
abstract = "Background: Obese patients have myocardial structural and functional alterations related to insulin resistance. Hypothesis: The purpose of the study was to analyze the effects of rosiglitazone, an insulin sensitizer agent, on cardiac morphometry and functioning. Methods: In 2 groups of sex- and age-matched, nondiabetic, obese patients (5 men and 7 women, age 19-51 y; group A: body mass index [BMI] 40.6±3.4 kg/m2; group B: BMI 42.6±2.7 kg/m2), we evaluated the basal insulin sensitivity index (HOMA[IS]), body composition by bioelectrical impedance analysis and 24-h blood pressure monitoring. Furthermore, all patients underwent conventional 2-Dimensional and color Doppler echocardiography, and pulsed-wave tissue Doppler imaging (TDI). After the baseline evaluation, all patients were put on a hypocaloric diet (70{\%} basal metabolic rate) plus placebo if they were in group A, or plus rosiglitazone (4 mg twice daily; Avandia [GlaxoSmithKline plc., Brentford, Middlesex, United Kingdom]) if they were in group B, for 6 mo. Results: Significant decreases in body weight, total fat mass, BMI, and systolic blood pressure were registered in both groups. Rosiglitazone administration appeared more efficient in improving HOMA(IS) (mean difference: 0.30±0.19 versus 0.11±0.21, p",
keywords = "Left ventricular function, Obesity, Rosiglitazone, Tissue doppler imaging",
author = "Amelia Brunani and Antonio Liuzzi and AnnaMaria Titon and Salvatore Graci and Giovanna Castagna and Viberti, {Gian Carlo} and Gondoni, {Luca A.}",
year = "2008",
month = "12",
doi = "10.1002/clc.20339",
language = "English",
volume = "31",
pages = "602--606",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Evaluation of rosiglitazone administration on cardiovascular function in severe obesity

AU - Brunani, Amelia

AU - Liuzzi, Antonio

AU - Titon, AnnaMaria

AU - Graci, Salvatore

AU - Castagna, Giovanna

AU - Viberti, Gian Carlo

AU - Gondoni, Luca A.

PY - 2008/12

Y1 - 2008/12

N2 - Background: Obese patients have myocardial structural and functional alterations related to insulin resistance. Hypothesis: The purpose of the study was to analyze the effects of rosiglitazone, an insulin sensitizer agent, on cardiac morphometry and functioning. Methods: In 2 groups of sex- and age-matched, nondiabetic, obese patients (5 men and 7 women, age 19-51 y; group A: body mass index [BMI] 40.6±3.4 kg/m2; group B: BMI 42.6±2.7 kg/m2), we evaluated the basal insulin sensitivity index (HOMA[IS]), body composition by bioelectrical impedance analysis and 24-h blood pressure monitoring. Furthermore, all patients underwent conventional 2-Dimensional and color Doppler echocardiography, and pulsed-wave tissue Doppler imaging (TDI). After the baseline evaluation, all patients were put on a hypocaloric diet (70% basal metabolic rate) plus placebo if they were in group A, or plus rosiglitazone (4 mg twice daily; Avandia [GlaxoSmithKline plc., Brentford, Middlesex, United Kingdom]) if they were in group B, for 6 mo. Results: Significant decreases in body weight, total fat mass, BMI, and systolic blood pressure were registered in both groups. Rosiglitazone administration appeared more efficient in improving HOMA(IS) (mean difference: 0.30±0.19 versus 0.11±0.21, p

AB - Background: Obese patients have myocardial structural and functional alterations related to insulin resistance. Hypothesis: The purpose of the study was to analyze the effects of rosiglitazone, an insulin sensitizer agent, on cardiac morphometry and functioning. Methods: In 2 groups of sex- and age-matched, nondiabetic, obese patients (5 men and 7 women, age 19-51 y; group A: body mass index [BMI] 40.6±3.4 kg/m2; group B: BMI 42.6±2.7 kg/m2), we evaluated the basal insulin sensitivity index (HOMA[IS]), body composition by bioelectrical impedance analysis and 24-h blood pressure monitoring. Furthermore, all patients underwent conventional 2-Dimensional and color Doppler echocardiography, and pulsed-wave tissue Doppler imaging (TDI). After the baseline evaluation, all patients were put on a hypocaloric diet (70% basal metabolic rate) plus placebo if they were in group A, or plus rosiglitazone (4 mg twice daily; Avandia [GlaxoSmithKline plc., Brentford, Middlesex, United Kingdom]) if they were in group B, for 6 mo. Results: Significant decreases in body weight, total fat mass, BMI, and systolic blood pressure were registered in both groups. Rosiglitazone administration appeared more efficient in improving HOMA(IS) (mean difference: 0.30±0.19 versus 0.11±0.21, p

KW - Left ventricular function

KW - Obesity

KW - Rosiglitazone

KW - Tissue doppler imaging

UR - http://www.scopus.com/inward/record.url?scp=58149098313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149098313&partnerID=8YFLogxK

U2 - 10.1002/clc.20339

DO - 10.1002/clc.20339

M3 - Article

VL - 31

SP - 602

EP - 606

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 12

ER -